Dimerix Stock

Dimerix FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Dimerix (DXB.AX) as of Sep 3, 2026 is -294.54 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 41.11 % — a change of -816.44% (lower).

FCF Conversion

-294.54 %

YoY

-816.44%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Dimerix is 2026 -294.54 % . FCF Conversion Rate (FCF/EBITDA) of Dimerix was 2025 41.11 % . It decreases by -816.44% lower compared to the previous year.

The Dimerix FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
97.26 AUD
Jan 1, 2019
95.55 AUD
Jan 1, 2020
105.06 AUD
Jan 1, 2021
99.97 AUD
Jan 1, 2022
128.18 AUD
Jan 1, 2023
92.23 AUD
Jan 1, 2024
41.11 AUD
Jan 1, 2025
-294.54 AUD
The Dimerix FCF Conversion history
YEARFCF ConversionYoY
-294.54 %-816.44%
41.11 %-55.43%
92.23 %-28.04%
128.18 %+28.21%
99.97 %-4.84%
105.06 %+9.95%
95.55 %-1.77%
97.26 %-8.39%
106.17 %+303.93%
26.28 %-67.76%
81.52 %-24.20%
107.55 %
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

FCF Conversion Rate (FCF/EBITDA) of Dimerix is -294.54 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Dimerix changed from 41.11 % to -294.54 %, representing a -816.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Dimerix since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Dimerix

All Key Metrics — Dimerix